NovaBay Pharmaceuticals, Inc. (NYSE:NBY) has a beta value of 3.9 and has seen 1,173,287 shares traded in the last trading session. The company, currently valued at $38.38 Million, closed the last trade at $1.15 per share which meant it lost -$0.04 on the day or -3.36% during that session. The NBY stock price is -68.7% off its 52-week high price of $1.94 and 79.13% above the 52-week low of $0.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.31 Million shares traded. The 3-month trading volume is 5.34 Million shares.

The consensus among analysts is that NovaBay Pharmaceuticals, Inc. (NBY) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) trade information

Despite being -3.36% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jul 21 when the NBY stock price touched $1.45 or saw a rise of 20.69%. Year-to-date, NovaBay Pharmaceuticals, Inc. shares have moved 79.69%, while the 5-day performance has seen it change -28.57%. Over the past 30 days, the shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) have changed 5.02%. Short interest in the company has seen 1.24 Million shares shorted with days to cover at 0.23.

Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 160.87% from current levels. The projected low price target is $3 while the price target rests at a high of $3. In that case, then, we find that the current price level is +160.87% off the targeted high while a plunge would see the stock lose 160.87% from current levels.

NovaBay Pharmaceuticals, Inc. (NBY) estimates and forecasts

Figures show that NovaBay Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +84.47% over the past 6 months, with this year growth rate of -54.17%, compared to 11.9% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 64.3% and -500% for the next quarter. Revenue growth from the last financial year stood is estimated to be +54%.

2 analysts offering their estimates for the company have set an average revenue estimate of $2.85 Million for the current quarter. 2 have an estimated revenue figure of $2.33 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $1.65 Million and $1.61 Million respectively for this quarter and the next, and analysts expect sales will grow by 72.7% for the current quarter and 44.3% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +42.4% over the past 5 years. Earnings growth for 2020 is a modest -25.3%.